Stoke Therapeutics Inc
STOK13.068USD
+0.158+1.23%
交易中 （美東）報價延遲15分鐘
713.47M總市值
14.19本益比TTM
關於 Stoke Therapeutics Inc 公司
Stoke Therapeutics, Inc. 是一家生物技術公司，致力於通過使用基於核糖核酸 (RNA) 的藥物上調蛋白質表達來解決嚴重疾病的根本原因。該公司通過其專有的靶向增強核基因輸出 (TANGO) 方法，致力於開發反義寡核苷酸 (ASO) 以選擇性恢復蛋白質水平。其首款化合物 STK-001 正在進行臨牀試驗，用於治療 Dravet 綜合徵，這是一種嚴重的漸進性遺傳性癲癇。TANGO 旨在通過增加或刺激健康基因的蛋白質輸出來恢復缺失的蛋白質，從而補償無功能的基因副本。該公司正在開發 STK-002，用於治療最常見的遺傳性視神經疾病常染色體顯性視神經萎縮 (ADOA)。該公司的初始重點是單倍體不足以及中樞神經系統和眼睛疾病。
公司簡介
公司代碼STOK
公司名稱Stoke Therapeutics Inc
上市日期Jun 19, 2019
CEOMr. Ian F. Smith, CPA
員工數量128
證券類型Ordinary Share
年結日Jun 19
公司地址45 Wiggins Avenue
城市BEDFORD
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編01730
電話17814308200
網址https://www.stoketherapeutics.com/
公司代碼STOK
上市日期Jun 19, 2019
CEOMr. Ian F. Smith, CPA
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Prof. Dr. Adrian R. Krainer, Ph.D.
Prof. Dr. Adrian R. Krainer, Ph.D.
Independent Director
Independent Director
404.72K
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Director
Director
139.35K
+43.83%
Mr. Jonathan Allan, J.D.
Mr. Jonathan Allan, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
25.83K
+55.93%
Dr. Barry S. Ticho, M.D., Ph.D.
Dr. Barry S. Ticho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Arthur A. Levin, Ph.D.
Dr. Arthur A. Levin, Ph.D.
Independent Director
Independent Director
--
--
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
--
--
Mr. Thomas Leggett
Mr. Thomas Leggett
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Arthur O. Tzianabos, Ph.D.
Dr. Arthur O. Tzianabos, Ph.D.
Interim Executive Chairman of the Board
Interim Executive Chairman of the Board
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Prof. Dr. Adrian R. Krainer, Ph.D.
Prof. Dr. Adrian R. Krainer, Ph.D.
Independent Director
Independent Director
404.72K
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Director
Director
139.35K
+43.83%
Mr. Jonathan Allan, J.D.
Mr. Jonathan Allan, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
25.83K
+55.93%
Dr. Barry S. Ticho, M.D., Ph.D.
Dr. Barry S. Ticho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Arthur A. Levin, Ph.D.
Dr. Arthur A. Levin, Ph.D.
Independent Director
Independent Director
--
--
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
--
--
收入明細
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
United States
158.57M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 7月31日 週四
更新時間: 7月31日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Lynx1 Capital Advisors LLC
9.69%
RTW Investments L.P.
9.38%
Baker Bros. Advisors LP
8.49%
Redmile Group, LLC
8.22%
Skorpios Trust
5.96%
Other
58.26%
持股股東
持股股東
佔比
Lynx1 Capital Advisors LLC
9.69%
RTW Investments L.P.
9.38%
Baker Bros. Advisors LP
8.49%
Redmile Group, LLC
8.22%
Skorpios Trust
5.96%
Other
58.26%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
42.57%
Investment Advisor
42.51%
Research Firm
15.81%
Hedge Fund
13.38%
Individual Investor
4.63%
Sovereign Wealth Fund
0.58%
Bank and Trust
0.21%
Pension Fund
0.16%
Venture Capital
0.07%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
299
62.92M
115.25%
-5.63M
2025Q1
306
66.97M
122.66%
-2.21M
2024Q4
301
61.22M
115.58%
-8.44M
2024Q3
297
61.15M
115.51%
-9.18M
2024Q2
284
64.23M
122.75%
+5.19M
2024Q1
273
57.18M
122.36%
+3.72M
2023Q4
261
48.04M
104.80%
-6.40M
2023Q3
264
46.81M
105.69%
-6.29M
2023Q2
260
49.41M
111.78%
-2.48M
2023Q1
272
47.84M
108.41%
-17.61M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Lynx1 Capital Advisors LLC
5.29M
9.69%
+104.74K
+2.02%
Mar 31, 2025
RTW Investments L.P.
5.12M
9.38%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
4.63M
8.49%
--
--
Mar 31, 2025
Redmile Group, LLC
4.49M
8.22%
-107.65K
-2.34%
Mar 31, 2025
Skorpios Trust
3.26M
5.96%
-3.65M
-52.85%
Jun 18, 2025
Morgan Stanley & Co. LLC
3.22M
5.89%
+255.18K
+8.62%
Mar 31, 2025
TD Securities, Inc.
3.17M
5.81%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.83M
5.18%
+1.23K
+0.04%
Mar 31, 2025
The Vanguard Group, Inc.
2.78M
5.09%
+53.00K
+1.95%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.47M
4.52%
+2.30M
+1394.59%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
WisdomTree BioRevolution Fund
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
Global X Genomics & Biotechnology ETF
0.61%
ALPS Medical Breakthroughs ETF
0.42%
iShares Health Innovation Active ETF
0.34%
Fidelity Fundamental Small-Mid Cap ETF
0.16%
SPDR S&P Biotech ETF
0.15%
iShares Micro-Cap ETF
0.11%
Direxion Daily S&P Biotech Bull 3X Shares
0.08%
ProShares Ultra Nasdaq Biotechnology
0.07%
查看更多
WisdomTree BioRevolution Fund
佔比1.16%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.86%
Global X Genomics & Biotechnology ETF
佔比0.61%
ALPS Medical Breakthroughs ETF
佔比0.42%
iShares Health Innovation Active ETF
佔比0.34%
Fidelity Fundamental Small-Mid Cap ETF
佔比0.16%
SPDR S&P Biotech ETF
佔比0.15%
iShares Micro-Cap ETF
佔比0.11%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.08%
ProShares Ultra Nasdaq Biotechnology
佔比0.07%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
